Good you update and pipeline XXXX begin afternoon, thank an and financial and fourth with recent results year-end then quarter review and activities. on business update call. our will for I our joining TRACON's
Financial Following and December ended XX Chief review financial Officer, that, Scott Brown, results our months XX, will our for X XXXX. the
taking by we questions. conclude Finally, your will
pivotal ENVASARC evaluating I'll combination progress an with a begin agent ENVA update continued single ongoing with as our with on the Yervoy. trial, and in
We completion occur UPS, U.K. U.S. the have accruing enrollment before treated patients of to and ENVASARC, XXX-milligram now at enrolled MFS, is XXXX. the in site Accrual nearly of dose the XX XXX continues patients with which is the the of anticipated one at or to refractory XX exceed end ENVA in sites and into projections
the Yervoy from ENVA. ENVA at trial of previous and efficacy the were data in X dose enrolled safety patients interim efficacy noted instituted in the we only reviewed with safety patients objective XXX-milligram a weight futility reported Responses review patients. X announced December, evaluations who dose the that review completed in efficacy ENVASARC single was more by cohorts cohort each was XXX-milligram DMC satisfied with prespecified that into than XX combination well tolerated interim a assessed following The independent minimum blinded event included and regardless weeks In response in XX related double-digit data scans. of each central of ENVA serious patients of DMC of treated rule. of in XX on-treatment the from rate the adverse that monotherapy at the of
planned trial as dose. the the recommended DMC The ENVA XXX-milligram at continue
responses, or objective out exceed rate response of primary blinded only interim the treatment an meaningful, level endpoint reminder, response to or a double-digit the a with is box objective the achieve UPS refractory we rate, rate indicating the response a of to is and of at independent time of confirmed X review, response Votrient fatal the is objective by endpoint cohort toxicity. study central defines on each liver objective RECIST that XX of for drug primary patients approved primary of black analysis a response satisfies rate MFS. X% As the in study. by track the Votrient, the with that endpoint XX.XX% warning for a Notably, Therefore, are statistically
is to in goal ENVASARC, efficacious both therefore, Our that demonstrate more than is ENVA safer Votrient. and
the in analysis accrual protocol Given we to are the mandated ENVASARC track the for the robust second trial, into third DMC on interim quarter. the perform efficacy
least that at X X During scans futility will in efficacy followed have apply patients X in a committee interim rule continue requires to who the responses into each to been on-study permit accrual cohort. order us XX for assessment, months
review development of designation orphan on to or filing received Yervoy. discuss combination Track expedite that designation on we based X a therapy, Fast targeting rate data from ENVA drug prior as and lines plan X We in we complements might UPS response progressed for rate X MFS receive up important pleased single-agent ENVA observed a designation in or to subtypes ENVA. FDA to of strategy have XXXX, a other were the trials and we Furthermore, holds very the in that ENVA ENVASARC. advantages and soon BLA inhibitors for XX% the Based XX% either MFS, UPS activity in regulatory sarcoma on refractory the determine This of in the to as we are approach with and checkpoint of cohort. responses response in for
potentially treatment a our YHXXX, Phase inhibitor, from checkpoint second to clinical August, IND In our FDA Biopharma we sites In site I/II antibody initiate October trial. we first patients CRO-independent patients are best-in-class that of CTLA-X the the therapy. received now open, XXXX. Eucure trial October, patients, approved have of licensed in we using product the for of to the a development prior initiated dosed not including sarcoma in and on research. Moving YHXXX TRACON's platform have of multiple Several who
the conducted trial YHXXX of as II dose I X toripalimab. our trials agent X data trials PD-X initial with Our Eucure. in and by Phase single YHXXX from antibody, a demonstrated completed These recommended partner, combination the leverages Phase
doxorubicin triplet evaluate that Phase a and trial doxorubicin treatment care sponsored for I/II sarcoma. is frontline standard ENVA includes as of YHXXX, Our chemotherapy clinical will current the
the The in the second trial half of combination doublet the assesses I therapy well of that the doxorubicin. Phase expect Phase of And as YHXXX and I to this we data the tolerability ENVA includes triple report the year. as portion of
in rate subtypes Thereafter, rare compared of the of II assess sarcoma superior will standard of with trial treatment combination historical common the demonstrating response Phase rates portion agents. to care to the intent using and response data the
we historical response compare single of agent rate response to therapy rate doxorubicin. In XX% like chondrosarcoma and liposarcoma, the rare triple plan subtypes case XX% and leiomyosarcoma In sarcoma the of to to to or doublet intend of to for is historical the sarcoma, we assess compared where part rates highly the alveolar chemotherapy single-agent response to rate YHXXX inhibition. not of chemotherapy response ENVA study soft checkpoint and effective, the
of that to of One respond trial subtypes is the objectives doxorubicin. sarcoma the I/II combination of best to of YHXXX the and determine Phase ENVA, this
Assuming FDA benefit. a trial potential to survival the trial of in positive a demonstrate ENVASARC the require pivotal and trial randomized results accelerated approval will ENVA,
that the trial I/II I will sarcoma patients to combination This to Phase ENVA point. the single-agent YHXXX, triplet shown the trial doxorubicin on with would and well end to MFS data this described to with as PFS as triple post-approval be as therapy and III from doxorubicin with expected other of subtypes trial UPS respond earlier. compare expect based We enroll Phase
and of ENVA the planned our of We trial submission data to prior the initiate on expect design to sarcoma refractory in discuss accelerated a approval accrual from FDA for BLA with frontline ENVASARC. based
is therapies sales ENVA in-licensed potential $XXX in of the parity MFS in initial is solely is refractory in important forecasted immuno-oncology goal UPS peak the million inhibition million at annual revenues the indications with It the not sarcoma sarcoma. annual strategic the to together pricing where and sarcoma ENVA in is understand rare X subtypes $XXX and of expected in commercialize to checkpoint in demonstrated. revenue activity Our
TRACON's is ENVA be Our Moreover, significantly indications. broadly enhanced strategy would opportunity sarcoma-driven sales revenue part to by settings the sarcoma adjuvant combination neoadjuvant together believe marking patients create supplemental and in by YHXXX a and with clinical to sarcoma. development front-line benefit in seeking the designed ENVA of for as total we treatment
checkpoint trial Cancer XX treatment. the randomized and X of X, of pleased non-squamous, to maintenance durvalumab Institute non-small cell to to trial, TRCXXX Institute are National fund In a benefit adding inhibitors, lung we Last therapy continues standard assessing assess The current of addition year, TRCXXX that cancer of will initiated stage by our development the TRCXXX. Cancer consolidated inhibitor, in cisplatin to pemetrexed, chemoradiation. the followed Phase enroll treatment combination repair radiation National DNA, our in damage patients II X-arm with care
the an is Multiple are PFS, open to to XXXX. is U.S. endpoint PFS The XX%. trial results designed trial the XX% expected of and are detect and the for in sites final in year at improvement primary enrollment in from X
the fourth checkpoint as in in Our TJXXXX a that Tecentriq. clinical-stage asset combination and Phase the TRACON study single antibody CDXX inhibitor is I agent evaluated a with
TRACON triggers trial, clinical completed data non-royalty royalty option then TJXXXX. of revenue which acquire not greater analysis and have I-Mab does a our the We If portion revenue entitled is to to provision. I-Mab option exercise their share of to
provide disputes with our I-Mab. an Next, I on will legal update
entered the to We either from in I-Mab prevailing both the dispute commenced into on counter declare arbitration, arbitration seeking million the damages be in resolution arbitration I-Mab TRACON alleged assuring June reminder, rules over were of the attorney's obligations provisions, in after may I-Mab our in party contractual contractual had in fees the a of November XXXX. of breaches. $XXX tribunals based Under I-Mab not breach to filed the awarded concerning at breached XXXX initiated they As recover that discretion. applicable its also invoked agreements agreement. arbitration claims
limited arguments discrete XXXX, with of I-Mab law, briefing X. November heard February Tribunal post-hearing the and alleged were breaches X, an X the submit Commerce in On December our agreements before the of an Chamber for Arbitration briefs of New Tribunal XXXX, to on invited York International parties to additional submitted by In issues were both under May. the late Tribunal
respective this Following indicate award. Tribunal to their submission, submissions. it the cost submitted did render expects not that when The party
Tribunal the quarter. preparation the to award, to along However, award in far final and we their of their did and Tribunal final continue expect they note, deliberations provide a this are
predict complex. the The the arbitration. outcome of cannot claims are the under arbitration we Accordingly,
any, damages, our under awarded to We are to estimate if Tribunal. arbitration, Pending the that of meet unable of may the be of by continue terms amount of agreements. obligations we the results both the recovery
the We their announced an when update Tribunal award. provide will promptly
source. on based $XX the $XX.X into amount in of announcement from capital nonrecourse through and recently an In the conditions will available challenging of entered to to the and and $X.X December subject forth expected we period. financing set markets, an exceeding be to the a in agreement. we to available secure Given partners lesser after being other amount another awarded the nondilutive, threshold the the important. award total be With XX% award the the to arbitration quarter. December, new is million total, this capital the decision award to million million over funded expectation up secured remainder existing Of $XX award multiyear up funded was capital its nondilutive available corporate and satisfaction additional In or related meantime, million the
of to collection nonrecourse repaid support I-Mab arbitration will financing arbitration. option extends to that million. crash while a varying the outcome trial upon agreement matters robust rates our I-Mab $X on the the with wait elapse award of their notification funding the be runway of other certain we regarding time of the This The and any pivotal and depend TJXXXX for the at terminate related I-Mab funding from binding accrual from the to ENVASARC
of through we product one organizations. our enabled clinical the cash As through we us opportunities for have to as noted believe capital most we development nondilutive CRO in further the positions efficient that past, expect position development platform our supplement independent
expect X to continue We our nondilutive potential to ways to in for that platform provide capital TRACON. leverage
fixed drug using to Johnson. lower continue evaluate an CRO, candidates, at a whereby premium cost structure & we a clinical trials at in past, pay-for-performance for our is performs example, a we TRACON model. This a cost used compared aligned the to to Johnson First, still with but
independently to a to model, company explore to use proprietary capabilities whereby internalize capabilities know-how are operations with our exceed we continue and share clinical new contracting enable we trials. to avoid to CROs Second, franchise these to paid clinical and another
could CRO savings the solution has our become substantial of we typically in higher trials strong result to contracted at the earned trials experience to and product to companies credibility at partner. compared and over independent cost wish our as compelling As and been for We quality an reap TRACON, to for at believe be a who faster time, platforms such investment rewards that development time lower expected cost believe conducting CROs.
an this update time, our on provide will At financials. Scott
